CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
四种已获批 CAR-T 细胞疗法治疗多发性骨髓瘤的疗效与安全性比较
英文原题：Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.
查看英文原题
Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管新型疗法取得显著进展，多发性骨髓瘤（MM）仍会不可避免地复发，因而目前仍无法治愈。嵌合抗原受体（CAR）T细胞疗法是一种创新免疫疗法，在复发/难治性（R/R）MM患者中显示出显著疗效。迄今，美国和中国已批准四种靶向B细胞成熟抗原（BCMA）的CAR-T 细胞疗法用于治疗R/R MM：伊德卡布塔基仑赛、西达基奥仑赛、伊基奥仑赛和泽沃基奥仑赛。尽管这四种疗法在R/R MM中均取得令人鼓舞的缓解率，但仍缺乏对其疗效和毒性特征的全面比较分析。本综述比较了这四种已获批BCMA靶向CAR-T 细胞疗法的疗效和安全性，并讨论观察到差异的潜在原因，以及可能进一步改善这一革命性疗法临床结局的策略。
展开英文摘要原文
Despite significant advances in novel therapies, multiple myeloma (MM) remains incurable due to inevitable relapse. Chimeric antigen receptor (CAR) T-cell therapy is an innovative immunotherapy that has demonstrated remarkable efficacy in patients with relapsed/refractory (R/R) MM. To date, four B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies have been approved in the United States and China for the treatment of R/R MM: idecabtagene vicleucel, ciltacabtagene autoleucel, equecabtagene autoleucel, and zevorcabtagene autoleucel.
Although these four CAR T-cell therapies have achieved encouraging response rates in R/R MM, a comprehensive comparative analysis of their efficacy and toxicity profiles is still lacking. In this review, we compare the efficacy and safety of these four approved BCMA-directed CAR T-cell therapies.
We also discuss potential factors underlying the observed differences and highlight strategies that may further improve the clinical outcomes of this revolutionary therapy.
论文信息
- 作者
- Song Z、Fu Q、Du J
- 单位
- Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.China
- 文献类型
- 综述 · 对照研究
- 期刊
- Hematological oncology2026 Mar
- 原文标识
- PubMed 41721717 · DOI 10.1002/hon.70179